Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
NCT01491100 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1085
Last updated 2018-04-05
Summary
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
Conditions
Interventions
- DRUG
-
Interferon beta-1b (Betaseron, BAY86-5046)
Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Min Age
- 12 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2016-12-22
- Completion
- 2017-04-05
Countries
- Albania
- Algeria
- Argentina
- Belgium
- Czechia
- Egypt
- France
- Germany
- Greece
- Hungary
- Israel
- Kazakhstan
- Netherlands
- Portugal
- Saudi Arabia
- Tunisia
- Turkey (Türkiye)
More Related Trials
-
Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon
NCT01766063 ·Status: COMPLETED
-
Depression and Fatigue in MS Patients Treated With Betaferon.
NCT01354665 ·Status: COMPLETED
-
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00206635 ·Status: COMPLETED
-
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
NCT01031459 ·Status: COMPLETED
-
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
NCT00313976 ·Status: WITHDRAWN ·Phase: PHASE3
-
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
NCT01075880 ·Status: COMPLETED
-
Betaferon Use in Children and Adolescents With Multiple Sclerosis
NCT03577977 ·Status: COMPLETED
-
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
NCT03408093 ·Status: COMPLETED
-
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
NCT03134573 ·Status: COMPLETED
-
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
NCT01142518 ·Status: COMPLETED
-
Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period
NCT01076595 ·Status: COMPLETED
-
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
NCT01795872 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
NCT01142557 ·Status: COMPLETED
-
Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis
NCT01184833 ·Status: COMPLETED
-
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
NCT00928967 ·Status: COMPLETED
-
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
NCT00219908 ·Status: TERMINATED ·Phase: PHASE2
-
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
NCT00185211 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis
NCT01122056 ·Status: COMPLETED ·Phase: NA
-
BENEFIT Extension Study
NCT00544037 ·Status: COMPLETED
-
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
NCT00441103 ·Status: COMPLETED ·Phase: PHASE3
-
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
NCT00235989 ·Status: COMPLETED ·Phase: PHASE2
-
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
NCT01142492 ·Status: COMPLETED
-
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
NCT01158183 ·Status: COMPLETED
-
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
NCT01233245 ·Status: COMPLETED
-
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
NCT00493116 ·Status: COMPLETED ·Phase: PHASE4